The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | MRD in multiple myeloma: prognosis, a clinical trial endpoint, and guiding treatment decisions
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the role of measurable residual disease (MRD) in multiple myeloma. MRD has prognostic significance, can evaluate treatment responses, and can be used to guide treatment decisions. Additionally, MRD has gained FDA approval as an endpoint in myeloma clinical trials. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria/Consultancy: Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD, Mundipharma-EDO.
